Strontium Ranelate (S12911; Distrontium renelate)

Description: Strontium Ranelate (S-12911; Distrontium renelate; Protelos or Protos) is an approved antiosteoporotic drug in EU, it can also slow the course of osteoarthritis of the knee by both increasing bone formation and reducing bone resorption, leading to a rebalance of bone turnover in favor of bone formation. Strontium Ranelate is a strontium(II) salt of ranelic acid acting as an activator of the calcium-sensing receptor (CaSR) in non skeletal cells. The drug is unusual in that it both increases deposition of new bone by osteoblasts and reduces the resorption of bone by osteoclasts. It is therefore promoted as a 'dual action bone agent' (DABA). The use is now restricted to treatment of severe osteoporosis in postmenopausal women at high risk for fracture.

References: Eur J Pharmacol. 2013 Apr 15; 706(1-3):41-7.